Sergio Penco

This inventor holds 73 USPTO granted patents and 1 published patent application and 5 EPO patents, primarily in Antitumor Compounds (CPC class 536 ). Top assignees: Farmitalia Carlo Erba, Sigma-Tau Industrie Farmaceutiche Riunite S.p.a., Farmitalia Carlo Erba S.r.l.. Active years: 1977-2012.

USPTO Granted Patents = 73 (Patent Applications = 1)

% Patents Active = 79.5

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 3.8

ph-index = 11

Forward Citations = 451(Granted Patents)

Forward Citations (Not Self Cited) = 387(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Milano, IT (1990)
Milan, IT (1977 - 2012)

Company Filing History:

25 out of 208

Farmitalia Carlo Erba

patents

14 out of 343

Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.

patents

10 out of 140

Farmitalia Carlo Erba S.r.l.

patents

4. 9 out of 48

Societa' Farmaceutici Italia

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori

patents

7. 2 out of 3

Sigma-Tau Research Switzerland S.a.

patents

8. 1 out of 3

Instituto Nazionale Per Lo Studio E La Cura Dei Tumori

patents

9. 1 out of 1

Istituo Nazionale Per Lo Studio E La Cura Dei Tumori

patent

10. 1 out of 1

Istituto Nazional Per Lo Studio E La Cura Dei Tumori

patent

11. 1 out of 220

Pharmacia Corporation

patents

12. 1 out of 1

Societa Farmaceutici Italia (Farmitalia Carlo Erba S.p.a.)

patent

13. 3 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1977-2012

Loading Chart...

Areas of Expertise:

Camptothecin Derivatives

Antiangiogenic Activity

Glycosaminoglycans

Antitumor Activity

Chiral Synthesis

Heterocyclic Compounds

Tyrosine Kinase

Chemosensitizing Agents

L-Carnitine Production

Natural Chrysanthone

Site Specific Alkylating Agents

Anthracyclines

73 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8222231 - Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect (2012-07-17),

2. 8101793 - Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities (2012-01-24),

3. 8067555 - Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect (2011-11-29),

4. 7790700 - Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect (2010-09-07),

5. 7781416 - Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect (2010-08-24),

6. 7728039 - Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives (2010-06-01),

7. 7705012 - Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents (2010-04-27),

8. 7612081 - 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups (2009-11-03),

9. 7589099 - 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists (2009-09-15),

10. 7449495 - Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities (2008-11-11),

11. 7351714 - 7-imino derivatives of camptothecin having antitumor activity (2008-04-01),

12. 7105492 - Camptothecin derivatives having antitumor activity (2006-09-12),

13. 7084166 - Bis-heterocyclic compounds with antitumour and chemosensitising activity (2006-08-01),

14. 6887883 - Use of natural chrysanthone compounds having antiangiogenic activity (2005-05-03),

15. 6589939 - Camptothecin derivatives having antitumor activity (2003-07-08),

Title: The Innovator: Sergio Penco, Pioneering Antiangiogenic Solutions

Introduction:

Sergio Penco, a visionary inventor based in Milan, Italy, has made significant contributions to the field of pharmaceuticals with a total of 73 patents under his name. His groundbreaking work revolves around developing derivatives of partially desulfated glycosaminoglycans with antiangiogenic properties, free of anticoagulating effects, and retinoid derivatives with potent antiangiogenic, antitumoral, and proapoptotic activities.

Latest Patents:

Among his latest patents are derivatives of partially desulfated glycosaminoglycans that demonstrate antiangiogenic activity without anticoagulant effects, and retinoid derivatives with multifaceted therapeutic applications in angiogenesis-related conditions and cancer treatment.

Career Highlights:

Sergio Penco's expertise and innovation have been instrumental in companies such as Farmitalia Carlo Erba S.p.A. and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. His pivotal role in these renowned pharmaceutical companies showcases his commitment to advancing medical science and improving patient outcomes through innovative solutions.

Collaborations:

Throughout his illustrious career, Sergio Penco has collaborated with distinguished professionals in the field, including Federico Maria Arcamone and Francesco Angelucci. Together, they have synergized their expertise to push the boundaries of pharmaceutical research and development, shaping the future of healthcare.

Conclusion:

In conclusion, Sergio Penco stands as a leading figure in the realm of pharmaceutical innovation, spearheading advancements in antiangiogenic therapies and cancer treatments. His prolific career, marked by numerous patents and successful collaborations, underscores his relentless pursuit of excellence and his unwavering dedication to revolutionizing the medical landscape for the betterment of society.